CO-DIAGNOSTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.25 USD | -1.57% |
|
-14.97% | -6.02% |
| 06-14 | Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform | CI |
| 05-13 | HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $2.50, Maintains Neutral Rating | MT |
| Sales 2024 * | 1.59M 2.18M | Sales 2025 * | 1.5M 2.05M | Capitalization | 39.1M 53.47M |
|---|---|---|---|---|---|
| Net income 2024 * | -41M -56.08M | Net income 2025 * | -42M -57.44M | EV / Sales 2024 * | 24.5 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 26.1 x |
| P/E ratio 2024 * |
-0.94
x | P/E ratio 2025 * |
-1.09
x | Employees | 155 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
Latest transcript on Co-Diagnostics, Inc.
More recommendations
More press releases
| 1 day | -1.57% | ||
| 1 week | -14.97% | ||
| Current month | +19.05% | ||
| 1 month | +23.76% | ||
| 3 months | +11.61% | ||
| 6 months | -6.02% | ||
| Current year | -6.02% |
1 week
1.22
1.59
1 month
1.011.73
Current year
1.001.73
1 year
0.981.89
3 years
0.9811.82
5 years
0.7930.99
10 years
0.6930.99
| Managers | Title | Age | Since |
|---|---|---|---|
Dwight Egan
CEO | Chief Executive Officer | 70 | 13-04-17 |
Brian Brown
DFI | Director of Finance/CFO | 48 | 21-02-21 |
Andrew Benson
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Reed L. Benson
LAW | General Counsel | 77 | 14-10-31 |
Richard Serbin
BRD | Director/Board Member | 79 | 17-04-30 |
Dwight Egan
CEO | Chief Executive Officer | 70 | 13-04-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.37% | 28 M€ | -4.06% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-28 | 1.25 | -1.57% | 73,993 |
| 24-06-27 | 1.27 | -4.51% | 252,397 |
| 24-06-26 | 1.33 | -0.75% | 85,311 |
| 24-06-25 | 1.34 | -3.60% | 114,031 |
| 24-06-24 | 1.39 | -5.44% | 134,835 |
Delayed Quote Nasdaq, June 28, 2024 at 04:00 pm
More quotes
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Companyâs technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the userâs mobile device.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.25
USD
Average target price
2
USD
Spread / Average Target
+60.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.02% | 39.1M | |
| -34.27% | 14.75B | |
| -54.93% | 2.22B | |
| +15.49% | 1.82B | |
| -14.07% | 1.43B | |
| +21.99% | 1.23B | |
| +1.25% | 784M | |
| -35.50% | 741M | |
| -36.65% | 723M | |
| -28.15% | 602M |
- Stock Market
- Equities
- CODX Stock
